Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA seeks advice on opioid-induced constipation drugs’ risks

This article was originally published in Scrip

Executive Summary

The FDA is convening a panel of its outside advisers over two days on 11-12 June to help the agency flesh out whether to require cardiovascular outcomes trials (CVOTs) for all, only specific or none of the peripherally active mu opioid receptor antagonists being developed to treat opioid-induced constipation (OIC) in patients with chronic non-cancer pain.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025518

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel